NEW YORK--(BUSINESS WIRE)--Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer’s disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) in Chicago, July 26-31.

Pfizer will also host an analyst briefing at ICAD to review its neuroscience pipeline and platform on Monday, July 28. In addition, Pfizer will sponsor a satellite symposium, “Innovative Approaches to Alzheimer’s Disease: Developing the Next Generation of Treatment,” on Tuesday, July 29.

“With the expected huge increase in the incidence of Alzheimer’s disease worldwide in the next 25 years, Pfizer’s neuroscience team has made this devastating illness our highest priority,” said Dr. Liam Ratcliffe, senior vice president and development head for Pfizer Neuroscience. “With new insights into the underlying causes of Alzheimer’s discovered in only the past few years, our scientists are working to develop new medicines that improve memory and other cognitive function, and importantly halt or significantly slow the progression of the disease. We are also working on approaches that could lead to earlier and better diagnosis.”

Pfizer’s investigational compounds target multiple pathways to combat AD, beta amyloid, the harmful protein that builds up in the brains of AD patients; amyloid plaques, the sticky deposits made of beta amyloid fragments that impair the function of brain cells; chronic inflammation of neurons, and loss of function across the synapses (or gaps) between neurons.

Data from Pfizer to be presented at the meeting include:

-- Receptor for Advanced Glycation End-products (RAGE) Antagonist:    Pfizer is in collaboration with TransTech Pharma to develop and    commercialize a portfolio of RAGE modulators. RAGE is a    cell-surface receptor that may play a key role in multiple aspects    of AD. Targeting RAGE for Alzheimer's is a novel approach and    Pfizer is pioneering this approach in the clinic.     -- Initial Phase II data on the safety and tolerability of Pfizer's       oral RAGE antagonist known as PF-04494700 will be presented by       Dr. Marwan Sabbagh, FAAN, director of The Cleo Roberts Center of       Clinical Research at the Sun Health Research Institute in Sun       City, AZ, on Wednesday, July 30th at 12:30 p.m. CST.     -- Preclinical data on the effect of PF-04494700 on chronic       inflammation and buildup of amyloid plaques - two abnormal       processes that are implicated in causing damage and death to       brain cells in AD - will also be presented by Dr. Jeffrey       Webster of TransTech Pharma on Monday, July 28th at 12:30 p.m.       CST.  -- Humanized Anti-Amyloid Monoclonal Antibody: Preclinical data on the    effect of PF-04360365, Pfizer's investigational monoclonal antibody    in Phase 1 trials, on beta amyloid levels in the brains of mice    will be presented by Dr. Thomas Lanz, Senior Scientist at Pfizer,     on Monday, July 28th at 12:30 p.m. CST. Monoclonal antibodies are    designed to selectively target a specific protein, which, in the    case of AD, is beta amyloid.

Additional Preclinical Research: Pfizer will also present data on a potential blood biomarker that could help in identifying patients with AD; two studies on the role of the brain’s immune system in the formation of amyloid plaques; a potential method of using novel imaging and microscopic analysis to quantify AD neuropathology, and early research on an additional investigational Pfizer compound on the inhibition of an enzyme in the brain.

About Alzheimer’s Disease

Alzheimer’s disease is a progressive disorder characterized by the gradual loss of memory and a decline in cognitive ability; changes in behavior, and a loss in ability to carry out daily activities. It places a tremendous burden on patients, those caring for them, and healthcare systems, costing the U.S. Government more than $148 billion annually. Alzheimer’s disease remains one of the world's most undiagnosed diseases, with only one-third of the world's approximately 18 million sufferers receiving treatment.

DISCLOSURE NOTICE: The information contained in this release is as of July 14, 2008. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information aboutcertain investigational compounds, including their potential benefits in treating Alzheimer’s disease, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such compounds as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in its reports on Form 10-Q and Form 8-K.